The use of GEM models for experimental cancer therapeutics

DMM Disease Models and Mechanisms

Volumn 1, Issue 2-3, 2008, Pages 83-86

  Gopinathan, Aarthi ^a   Tuveson, David A ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB;

BREAST CANCER; CANCER MODEL; CANCER THERAPY; DRUG EFFICACY; EDITORIAL; EXPERIMENTAL NEOPLASM; IMMUNE SYSTEM; LUNG ADENOCARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; HUMAN; IMMUNOLOGY; NEOPLASM; PATHOLOGY; TRANSGENIC ANIMAL; VASCULARIZATION; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 64249114690     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.000570     Document Type: Editorial

References (20)

1. Bocci, G., Danesi, R., Marangoni, G., Fioravanti, A., Boggi, U., Esposito, I., Fasciani, A., Boschi, E., Campani, D., Bevilacqua, G. et al. (2004). Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur. J. Pharmacol. 498, 9-18. (Pubitemid 39208055)
2. Boehm, T., Folkman, J., Browder, T. and O'Reilly, M. S. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407. (Pubitemid 28027321)
3. de Visser, K. E., Eichten, A. and Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37. (Pubitemid 43053650)
4. Dunn, G. P., Old, L. J. and Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360.
5. Faca, V. M., Song, K. S., Wang, H., Zhang, Q., Krasnoselsky, A. L., Newcomb, L. F., Plentz, R. R., Gurumurthy, S., Redston, M. S., Pitteri, S. J. et al. (2008). A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 5, e123. (Pubitemid 351919117)
6. Frese, K. K. and Tuveson, D. A. (2007). Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658.
7. Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A. et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450. (Pubitemid 38050041)
8. Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S. and Tuveson, D. A. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483. (Pubitemid 40719130)
9. Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R. et al. (2006). The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485-495. (Pubitemid 43832191)
10. Jia, L., Zhang, M. H., Yuan, S. Z. and Huang, W. G. (2005). Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J. Gastroenterol. 11, 447-450. (Pubitemid 40125262)
11. Kindler, H. L., Niedzwiecki, D., Hollis, D., Oraefo, E., Schrag, D., Hurwitz, H., McLeod, H. L., Mulcahy, M. F., Schilsky, R. L., Goldberg, R. M. et al. (2007). A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J. Clin. Oncol. 25, June 2007 Supplement.
12. Kulke, M. H., Demetri, G. D., Sharpless, N. E., Ryan, D. P., Shivdasani, R., Clark, J. S., Spiegelman, B. M., Kim, H., Mayer, R. J. and Fuchs, C. S. (2002). A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapyresistant metastatic colorectal cancer. Cancer J. 8, 395-399.
13. Politi, K., Zakowski, M. F., Fan, P. D., Schonfeld, E. A., Pao, W. and Varmus, H. E. (2006). Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496-1510. (Pubitemid 43830656)
14. Rottenberg, S. and Jonkers, J. (2007). Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist. Updat. 11, 51-60.
15. Rottenberg, S., Nygren, A. O., Pajic, M., van Leeuwen, F. W., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O. et al. (2007). Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA 104, 12117-12122. (Pubitemid 47185639)
16. Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H. et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4651-4661. (Pubitemid 44297818)
17. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holdsen, S. A., Chen, L. B., Singer, S., Fletcher, C. et al. (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 4, 1046-1052. (Pubitemid 28417337)
18. Shu, Q., Wong, K. K., Su, J. M., Adesina, A. M., Yu, L. T., Tsang, Y. T., Antalffy, B. C., Baxter, P., Perlaky, L., Yang, J. et al. (2008). Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of Medulloblastoma and Glioma. Stem Cells 26, 1414-1424.
19. Twombly, R. (2002). First clinical trials of endostatin yield lukewarm results. J. Natl. Cancer Inst. 94, 1520-1521.
20. Vantyghem, S. A., Wilson, S. M., Postenka, C. O., Al-Katib, W., Tuck, A. B. and Chambers, A. F. (2005). Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res. 65, 3396-3403. (Pubitemid 40524625)